Publications in collaboration with researchers from Hospital Vall d'Hebron (17)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

  3. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

2023

  1. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

    Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229

  2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  3. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021

    Journal of Medical Virology, Vol. 95, Núm. 12

2022

  1. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 12

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  3. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

    Frontiers in Cell and Developmental Biology, Vol. 10

  4. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

    ESMO Open, Vol. 7, Núm. 2

  5. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1248-1265

2021

  1. Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2008

  1. Immunotherapy for neurological diseases

    Clinical Immunology